Processa Pharmaceuticals (formerly Heatwurx) is a company focused on developing treatments for patients with an unmet medical need. Its product candidate, PCS499, is an oral tablet for the treatment of Necrobiosis Lipoidica, a necrotizing skin condition, caused by several pathophysiological changes. The company also investigates the use of PCS499 to treat radiation-related adverse effects in head and neck cancer.